NCT02536586View on ClinicalTrials.gov

A Study of LY3023414 in Japanese Participants With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

February 9, 2017

Study Completion Date

February 9, 2017

Conditions
Neoplasm
Interventions
DRUG

LY3023414

LY3023414 administered orally.

Trial Locations (2)

277 8577

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Chiba

104-0045,

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Tokyo

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT02536586 - A Study of LY3023414 in Japanese Participants With Advanced Cancer | Biotech Hunter | Biotech Hunter